Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma

采用5MCAR技术治疗外周T细胞淋巴瘤

• 批准号: 10351121
• 负责人: Michael S Kuhns
• 金额: $ 18.71万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10351121
• 关键词: Antigens; B-Cell NonHodgkins Lymphoma; Binding; Biological Models; Biomimetics; CAR T cell therapy; CD28 gene; CD3 Antigens; CD4 Positive T Lymphocytes; CD80 gene; CD8B1 gene; CTLA4 gene; Clinical; Clinical Trials; Cytotoxic T-Lymphocytes; Data; Development; Disease; Elements; Engineering; Generations; Goals; Head; Immunotherapy; Left; Libraries; Lymphocyte-Specific p56LCK Tyrosine Protein Kinase; Lymphoma; Molecular Machines; Operative Surgical Procedures; Outcome; Pathogenicity; Patients; Peptides; Peripheral; Prognosis; Publishing; Reporting; Research; Signal Transduction; Specificity; System; T cell response; T cell therapy; T-Cell Activation; T-Cell Immunologic Specificity; T-Cell Lymphoma; T-Cell Receptor; T-Lymphocyte; Technology; Testing; Therapeutic; Transmembrane Domain; Tumor Antigens; Work; base; chimeric antigen receptor; design; immune checkpoint blockade; improved; in vivo; innovation; insight; non-Hodgkin' s lymphoma patients; patient prognosis; personalized medicine; receptor; receptor binding; response; src-Family Kinases; success; tumor

PROJECT SUMMARY CD4+ T cells respond to peptide antigens presented by MHCII molecules (pMHCII) using a 5-module molecular machines composed of a receptor module [the T cell receptor (TCR)], three signaling modules (CD3, CD3, CD3), and a coreceptor module (CD4). Drawing upon this blueprint, we designed a biomimetic 5-module chimeric antigen receptor (5MCAR) system composed of a chimeric receptor module, built with pMHCII and TCR components (CRMpMHCII), that assembles with the CD3 signaling modules and works with a surrogate coreceptor (ScoR) to generate signals in response to specific TCRs. As we recently reported (Kobayashi, et al., PNAS 2020), 5MCAR-CTLs can specifically target and kill pathogenic CD4+ T cells that express TCRs that bind the CRMpMHCII. Given that peripheral T cell lymphomas (PTCLs) represent a unique type of pathogenic T cell for which treatment options are limited, and patient prognosis is poor, we are motivated to ask if our 5MCAR technology can be developed into a patient-specific PTCL therapy. As PTCLs are often derived from transformed CD4+ T cells and express a clonotypic TCR that represents a tumor-specific antigen, we consider them to be ideal targets for 5MCAR-CTLs. Accordingly, the goal of the current study is to establish a workflow whereby our 5MCAR technology is used to screen libraries of CRMpMHCII for mimotope CRMpMHCII that signal in response to the clonotypic TCR of a PTCL, and then use the identified mimotope CRMpMHCII to generate 5MCAR-CTLs for targeting the PTCL via its clonotypic TCR. When completed, the established workflow will provide a blueprint for adapting our 5MCAR technology into a personalized therapy to treat patients with PTCLs.

项目总结 CD4+T细胞对MHCII分子(PMHCII)提呈的多肽抗原的反应 由一个受体模块[T细胞受体(TCR)]，三个信号模块(CD3，CD3， CD3)和辅受体模块(CD4)。根据这一蓝图，我们设计了一种仿生5模组。 嵌合抗原受体(5MCAR)系统由嵌合受体模块组成，由pMHCII和pMHCII构建 TCR组件(CRMpMHCII)，与CD3信令模块组装并与代理组件一起工作 辅受体(SCOR)对特定的TCR产生信号。正如我们最近报道的(小林等人 ，PNAS 2020)，5MCAR-CTL可以特异性地靶向并杀伤表达TCRs的致病CD4+T细胞 绑定CRMpMHCII。鉴于外周T细胞淋巴瘤(PTCL)是一种独特的致病T细胞 细胞的治疗选择是有限的，患者预后很差，我们有动力问我们的5MCAR 这项技术可以发展成针对患者的PTCL疗法。因为PTCL通常源自 转化的CD4+T细胞，并表达代表肿瘤特异性抗原的克隆型TcR，我们 认为它们是5MCAR-CTL的理想靶点。因此，当前研究的目标是建立一个 我们的5MCAR技术用于筛选CRMpMHCII库中的模拟表位CRMpMHCII 响应PTCL的克隆型TCR的信号，然后使用识别的模拟表位CRMpMHCII来 通过其克隆型TCR产生针对PTCL的5MCAR-CTL。完成后，已建立的 工作流程将为将我们的5MCAR技术应用于个性化治疗提供蓝图 PTCL患者。